Medtronic Terminate AF Study

This is a multi-center, single-arm, prospective, non-randomized, interventional study. A
maximum of 160 subjects will be treated at up to 15 centers in the US. The study will include
male and female patients with a history of non-paroxysmal atrial fibrillation who are
undergoing concomitant cardiac surgery. Subjects will be followed and assessed after
procedure and for 12 months.

The purpose of this study is to evaluate the safety and effectiveness of the Cardioblate
Surgical Ablation iRF and CryoFlex hand held devices to support an indication expansion to
include treatment of non-paroxysmal atrial fibrillation to the product labeling.

Inclusion Criteria:

1. History of non-paroxysmal AF (persistent or longstanding persistent)

2. Concomitant indication for non-emergent open-heart surgery, eg,

1. Coronary artery bypass grafting

2. Valve repair or replacement

3. Able to take the anticoagulant warfarin or novel oral anticoagulants (NOAC)

Exclusion Criteria:

- Wolff-Parkinson-White syndrome

- NYHA Class = IV

- Left Ventricular Ejection Fraction ≤ 30%

- Need for emergent cardiac surgery (ie, cardiogenic shock) or redo open heart surgery

- Previous AF ablation, AV-nodal ablation, or surgical Maze procedure

- Contraindication for anticoagulation therapy

- Left atrial diameter > 6.0 cm

- Preoperative need for an intra-aortic balloon pump or intravenous inotropes

- Renal failure requiring dialysis or hepatic failure

- Life expectancy of less than 1 year

- Predicted risk of operative mortality >10% as assessed by STS Risk Calculator

- Pregnancy or desire to be pregnant within 12 months of the study treatment

- Current diagnosis of active systemic infection

- Active endocarditis

- Documented MI 30 days prior to study enrollment